Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France-Reference-Cited by-同舟云学术

Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France

Published:2017-03-30 Issue:5 Volume:79 Page:1051-1055
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Bonnet Clément,Boudou-Rouquette Pascaline,Azoulay-Rutman Esther,Huillard Olivier,Golmard Jean-Louis,Carton Edith,Noé Gaëlle,Vidal Michel,Orvoen Galdric,Chah Wakilian Anne,Villeminey Clémentine,Blanchet Benoit,Alexandre Jérôme,Goldwasser François,Thomas-Schoemann Audrey

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-017-3291-z.pdf

Reference19 articles.

1. Lees J, Chan A (2011) Polypharmacy in elderly patients with cancer : clinical implications and management. Lancet Oncol 12:1249–1257

2. De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995–2005

3. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–48

4. Thomas-Schoemann A, Blanchet B, Bardin C et al (2014) Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 89(1):179–196

5. Chan A, Tan SH, Wong CM (2009) Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 31(2):2379–2386

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors;JCO Oncology Practice;2024-09

2. Drug-Drug Interactions in Hospitalized Urological Patients: A Retrospective Cohort Study;Pharmacology;2024-07-30

3. A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients;Frontiers in Pharmacology;2023-09-28

4. Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information;Cardiovascular Drugs and Therapy;2023-05-01

5. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022;European Urology;2023-03